CEOs, Senior Executives Highlight Strategies, M&A, and Expansions at DCAT WeekBy
Chief executive officers and senior executives from DCAT member companies provided key updates on strategy, mergers and acquisitions, and expansions at the DCAT Member Company Announcement Forum held during DCAT Week in mid-March.
The executives highlighted key company activity impacting the pharmaceutical manufacturing value chain. SCHOTT, Catalent, Thermo Fisher Scientific, Cambrex, Lonza, BSP Pharmaceuticals, Servier CDMO, Selkirk Pharma, Seqens, Cerbios-Pharma, and ACG were among the companies taking the podium to provide their latest developments (see announcements below).
SCHOTT Plans $1-Billion Expansion in Pharma Packaging
Catalent Investing $214 Million to Expand Biologics Capabilities; Invests in Oral Delivery Capabilities
Thermo Fisher Scientific Investing $150 Million in Sterile Injectables Development and Manufacturing
Cambrex Updates Integration of Halo Pharma and Avista Pharma; Expands Small-Molecule API Mfg
Lonza Updates $100-Million Expansion for High-Potency APIs and Small-Molecule Mfg
BSP To Add High-Containment Capacity for Conjugation and Injectable Drug Products
Servier CDMO Invests $55 Million for Bioproduction and $7 Million for Industrial Prep Chromatography
New CDMO Selkirk Pharma Investing $30 Million in Aseptic Fill–Finish Facility
Seqens Investing $30 Million to Expand High-Potency Manufacturing
Cerbios-Pharma Investing in New High-Potency API Production Line and Conjugation Suite
ACG Expands Capsule Production in Brazil, India, and Croatia